What causes sjs ten

What It Is

Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) are life-threatening mucocutaneous reactions characterized by widespread blistering and epidermal detachment. SJS affects less than 10% of body surface area, while TEN involves 30% or more, with SJS/TEN overlap affecting 10-30%, representing a spectrum of the same pathophysiological process. Both conditions involve massive keratinocyte apoptosis leading to full-thickness epidermal necrosis and separation from the dermis. The mortality rate for TEN reaches 25-35% despite aggressive medical management, making early recognition and treatment critical.

The first cases of severe SJS-like reactions were documented in the 1920s, but the condition gained medical prominence in the 1950s when researchers identified associations with drug exposures. In 1993, the term Toxic Epidermal Necrolysis was formally standardized to describe the severe form with extensive body surface involvement. The discovery of HLA genetic associations in 2002 revolutionized understanding of SJS/TEN pathogenesis, leading to genetic screening programs in populations using allopurinol and carbamazepine. Clinical classification criteria established in 1993 standardized diagnosis and severity assessment based on percentage of body surface area affected.

SJS/TEN exists on a continuum of cutaneous and mucosal involvement severity, classified by the percentage of epidermis affected. Prodromal symptoms typically include fever, malaise, and upper respiratory symptoms preceding rash by 3-14 days. Mucous membrane involvement is nearly universal, affecting 90% of patients across oral, ocular, nasopharyngeal, and genital areas. Systemic complications include sepsis, organ failure, and electrolyte abnormalities that contribute significantly to mortality rates.

How It Works

SJS/TEN pathogenesis involves a complex T-cell mediated hypersensitivity reaction triggered by specific medications or infections. Offending drugs or antigens are processed by antigen-presenting cells and presented to cytotoxic T-lymphocytes (CD8+) through MHC-peptide interactions. The triggering antigen acts as a hapten, binding to native proteins and forming immunogenic complexes recognized by T-cells. HLA genetic variants determine peptide presentation efficiency, explaining why certain individuals develop severe reactions while others exposed to identical drugs remain unaffected.

A classic example of drug-induced SJS occurred in a 45-year-old patient at Johns Hopkins Hospital who developed severe SJS after 8 days of allopurinol treatment for gout. The patient presented with fever, blisters affecting 25% of body surface, and oral ulceration requiring hospitalization in the burn unit. Genetic testing confirmed HLA-B*5801 variant strongly associated with allopurinol-induced SJS. This case exemplifies typical presentation timing, clinical features, and the importance of HLA screening in populations using high-risk medications.

The pathophysiological mechanism involves keratinocyte apoptosis triggered by FasL-Fas interactions, granzyme-perforin pathways, and TNF-alpha signaling. Activated T-cells migrate to the skin and release cytotoxic granules that enter keratinocytes, triggering apoptotic cascades. Massive apoptosis causes loss of cell-cell adhesion molecules, leading to intraepidermal and subepidermal separation. Inflammatory infiltrate composed primarily of CD8+ T-cells and macrophages propagates tissue destruction, with systemic involvement causing multi-organ failure in severe cases.

Why It Matters

SJS/TEN carries mortality rates of 5-15% for SJS and 25-35% for TEN despite aggressive treatment, making prevention through drug screening paramount. Survivors experience significant long-term morbidity including blindness from ocular scarring (30% of survivors), chronic xerostomia, and severe contractures limiting function. Economic burden exceeds $1 million per patient when accounting for intensive care hospitalization, ophthalmologic care, and long-term rehabilitation. Early recognition and immediate cessation of causative drug can reduce mortality by up to 50% according to meta-analyses of treatment outcomes.

Prevention programs using HLA genetic screening have proven highly effective in high-risk populations, particularly among Han Chinese and other Asian populations using carbamazepine. The FDA approved carbamazepine-HLA-B*1502 screening in 2007, dramatically reducing SJS/TEN incidence among screened populations. Major pharmaceutical companies including Merck and Novartis have implemented screening recommendations for allopurinol and other high-risk medications. Healthcare systems in Taiwan and Thailand report 80-90% reduction in drug-induced SJS/TEN through widespread HLA screening programs.

Future prevention strategies focus on expanding HLA screening panels to identify additional genetic variants conferring risk with emerging medications. Therapeutic advances including intravenous immunoglobulin (IVIG), tumor necrosis factor-alpha inhibitors, and cyclosporine show promise in reducing mortality when applied early. Regenerative medicine approaches using cultured skin substitutes and stem cell therapies are under investigation for treating extensive epidermal loss. International SJS/TEN registries are expanding to provide better epidemiological data and identify additional drug culprits and genetic risk factors.

Common Misconceptions

Many healthcare providers incorrectly believe SJS/TEN is solely a drug-related condition, overlooking infectious causes in 5-10% of cases. Infections including Mycoplasma pneumoniae, HSV, and HIV can independently trigger SJS/TEN without drug exposure. This misconception leads to delayed recognition when infectious triggers are responsible, potentially delaying appropriate supportive care and antimicrobial treatment. Comprehensive history taking must evaluate both medication and recent infection exposure to identify all potential triggers.

A widespread misconception suggests SJS/TEN results from simple drug allergy or sensitivity, minimizing severity expectations and appropriate treatment urgency. SJS/TEN represents severe T-cell mediated cytotoxicity causing epidermal necrosis, fundamentally different from typical allergic reactions involving IgE-mediated mechanisms. This misunderstanding results in inadequate hospitalization rates and delayed transfer to specialized burn units equipped for management. Only 50-60% of SJS/TEN patients are admitted to intensive care despite mortality rates comparable to severe thermal burns.

Many patients and families believe topical treatments and supportive care are the only necessary management, misunderstanding systemic pathophysiology. While supportive care remains foundational, emerging evidence strongly supports systemic immunosuppression with IVIG, cyclosporine, or TNF-alpha inhibitors when initiated early. Studies demonstrate that systemic corticosteroids, once considered standard of care, may worsen outcomes and are now avoided in most protocols. Modern SJS/TEN management requires aggressive immunosuppression guided by systemic inflammation markers and respiratory status monitoring.